Compare FormFactor Inc. FormFactor Inc. Common Stock (FORM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FormFactor Inc. FormFactor Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $115 (market cap $10.01B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: FormFactor Inc. FormFactor Inc. Common Stock is far larger — about 2.1× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is more actively traded (1,668,577 versus 1,445,909). Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| FORM | TVTX | |
|---|---|---|
Market Cap | $10.01B | $4.88B |
Volume | 1,445,909 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $159.93 | $67.52 |
52-Week Low | $41.29 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.69B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FormFactor (FORM) trades at $128.09, down 1.68% on the day, amid a bullish technical setup with key support at $127. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28. Revenue and net income are projected to grow significantly in 2026, though valuation ratios remain elevated.
The outlook is positive, driven by strong AI-driven semiconductor demand and strategic collaborations, but high P/E and P/S ratios pose valuation risks. Analyst consensus is bullish with a $154.71 price target, though insider selling and negative cash flow in 2025 warrant caution.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FormFactor Inc. FormFactor Inc. Common Stock
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
